Limits...
Evaluation of hydrophobic nanoparticulate delivery system for insulin.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

Bottom Line: Insulin encapsulation efficiency was 95.7±1.2%.Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Insulin loaded hydrophobic nanoparticles were prepared by solvent diffusion followed by lyophilization. Nanoparticles were characterized for mean size by dynamic laser scattering and for shape by scanning electron microscopy. Insulin encapsulation efficiency, in vitro stability of nanoparticles in presence of proteolytic enzymes and in vitro release were determined by high pressure liquid chromatography analysis. The biological activity insulin from the nanopraticles was estimated by enzyme-linked immunosorbant assay and in vivo using Wister diabetic rats. Nanoparticles ranged 0.526±0.071 μm in diameter. Insulin encapsulation efficiency was 95.7±1.2%. Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.


Serum human insulin versus time profileSerum human insulin levels after oral administration of 20 IU/kg Insulin nanoparticles (▪), Placebo nanoparticles equivalent to 20 IU/ kg of insulin (▲), subcutaneous injection of 2 IU/kg Human insulin solution (♦), n=6 per group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3040864&req=5

Figure 0003: Serum human insulin versus time profileSerum human insulin levels after oral administration of 20 IU/kg Insulin nanoparticles (▪), Placebo nanoparticles equivalent to 20 IU/ kg of insulin (▲), subcutaneous injection of 2 IU/kg Human insulin solution (♦), n=6 per group.

Mentions: Human insulin nanoparticles (Group-3) showed significantly high serum human insulin concentration levels over the 4 to 12 h period were observed as compared to the placebo control (Group-1). Fig. 3 shows the serum human insulin concentration profile versus time for each group.


Evaluation of hydrophobic nanoparticulate delivery system for insulin.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

Serum human insulin versus time profileSerum human insulin levels after oral administration of 20 IU/kg Insulin nanoparticles (▪), Placebo nanoparticles equivalent to 20 IU/ kg of insulin (▲), subcutaneous injection of 2 IU/kg Human insulin solution (♦), n=6 per group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3040864&req=5

Figure 0003: Serum human insulin versus time profileSerum human insulin levels after oral administration of 20 IU/kg Insulin nanoparticles (▪), Placebo nanoparticles equivalent to 20 IU/ kg of insulin (▲), subcutaneous injection of 2 IU/kg Human insulin solution (♦), n=6 per group.
Mentions: Human insulin nanoparticles (Group-3) showed significantly high serum human insulin concentration levels over the 4 to 12 h period were observed as compared to the placebo control (Group-1). Fig. 3 shows the serum human insulin concentration profile versus time for each group.

Bottom Line: Insulin encapsulation efficiency was 95.7±1.2%.Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Insulin loaded hydrophobic nanoparticles were prepared by solvent diffusion followed by lyophilization. Nanoparticles were characterized for mean size by dynamic laser scattering and for shape by scanning electron microscopy. Insulin encapsulation efficiency, in vitro stability of nanoparticles in presence of proteolytic enzymes and in vitro release were determined by high pressure liquid chromatography analysis. The biological activity insulin from the nanopraticles was estimated by enzyme-linked immunosorbant assay and in vivo using Wister diabetic rats. Nanoparticles ranged 0.526±0.071 μm in diameter. Insulin encapsulation efficiency was 95.7±1.2%. Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.